Welcome to the e-CCO Library!

P672: Biologic therapy for Inflammatory Bowel Disease in Poland in 2020: nationwide data.
Year: 2022
Source: ECCO'22
Authors: Kucha, P.(1);Zagórowicz, E.(1,2);Walkiewicz, D.(3);Perwieniec, J.(3);Maluchnik, M.(3,4);Wieszczy, P.(2);Reguła, J.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P672: Drug therapy and monitoring for inflammatory bowel diseases: preliminary data from a multi-centre investigation in Asia
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Cai1, J. Shen1, J. Tong1, J. Lu1, Q. Zheng1, K. Wu2, J. Qian3, Z. Ran*1

Created: Friday, 22 February 2019, 9:41 AM
P672: Surgical and anti-TNFs combined therapy prevents Crohn's perianal fistula recurrence: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Xu P.-p.*1, Qiu Y.2, Jia Y.-l.1, Xu L.1, He C.-y.1, Han Z.1

Created: Wednesday, 20 February 2019, 10:36 AM
P672: Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: AnjieMD, S.(1)*;Hanžel, J.(2);Gecse, K.B.(1);D'Haens, G.R.(1);Brandse, J.F.(3);
Created: Friday, 14 July 2023, 11:12 AM
P673 Strategy of selecting anti-TNF agent in patients with Crohn’s disease: A multi-centre retrospective cohort study by the Osaka gut forum
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Amano, S. Shinzaki, T. Tashiro, Y. Otake, M. Tani, T. Yoshihara, S. Iwatani, Y. Tsujii, T. Inoue, Y. Hayashi, H. Iijima, T. Takehara, Osaka Gut Forum

Created: Thursday, 30 January 2020, 10:12 AM
P673: Achievement of tight control based on serum C-reactive protein and albumin correlated with better outcomes in Japanese Crohn’s disease patients treated with biologics
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Shiga*1, I. Abe1, M. Onodera1, R. Moroi1, M. Kuroha1, Y. Kanazawa1, Y. Kakuta1, Y. Kinouchi1,2, A. Masamune1

Created: Friday, 22 February 2019, 9:41 AM
P673: Intra-abdominal collections in Crohn's disease: outcomes following anti-TNF therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Subramaniam K.*1,2, Tweedale M.1, Pavli P.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P673: Microbial diversity in newly diagnosed treatment naïve Inflammatory Bowel Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Ellul , S.(1);Rausch , P.(2);Pisani , A.(3);Bang , C.(2);ellul , P.(3);Franke , A.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P673: The safety of rapid versus standard infliximab infusions in children with inflammatory bowel disease: a multi-centre retrospective cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jagt, J.(1,2)*;Galestin, S.(3);Benninga, M.(1);de Boer, N.(4);de Meij, T.(1);
Created: Friday, 14 July 2023, 11:12 AM
P673: Vedolizumab dose escalation as a way of recapturing response in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Sierra Morales1,2*, S. Birdi1, M.A. Samaan1, C. Brown-Clarke1, J. Duncan1, A. Stanton1, I. Koumoutsos1, S. Anderson1, S. Ray1, J. Mawdsley1, J. Sanderson1, P.M. Irving1

Created: Thursday, 21 February 2019, 9:14 AM
P674 Monitoring posologic change in adalimumab intensification dosing regimen from 40 mg every week to 80 mg every other week
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.T. Diz Lois Palomares1, Á. Porta Sánchez2, L. Elberdin Pazos2, B. González Conde1, M. Outeda Macías2, M.T. Vázquez Rey1, A. Guerrero Montañés1, E. Estévez Prieto1

Created: Thursday, 30 January 2020, 10:12 AM
P674: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Szántó1, A. L. Szíjártó2, D. Kata3, I. Földesi3, Z. A. Mezei4, A. Fábián1, A. Bálint1, R. Bor1, K. Farkas1, Á. Milassin1, M. Rutka1, Z. Szepes1, F. Nagy1, T. Bubán5, S. Lovas6, K. Palatka6, T. Molnár1

Created: Friday, 22 February 2019, 9:41 AM
P674: Clinical characteristics and management of Crohn’s disease in patients with residual disease after surgery compared with curative surgery: Results from PRACTICROHN study
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Domènech1*, M.D. Martín Arranz2, M. Iborra3, V. García4, A. Gutiérrez5, C. Taxonera6, L. Cea-Calvo7, C. Romero7, M. Barreiro-de Acosta8, B. Juliá7

Created: Thursday, 21 February 2019, 9:14 AM
P674: Definition of a microbial signature as a predictor of anti-TNFα treatment response
Year: 2021
Source: ECCO'21 Virtual
Authors: Oliver, L.(1);Busquets, D.(2);Amoedo, J.(1);Ramió-Pujol, S.(1);Malagón, M.(1);Serrano, M.(1);Bahí, A.(3);Lluansí, A.(3);Gilabert, P.(4);Miquel-Cusachs, J.O.(2);Sàbat, M.(5);Guardiola, J.(4);Serra-Pagès, M.(1);Garcia-Gil, J.(6);Aldeguer, X.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P674: Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in paediatric Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kang B.*1, Lee K.1, Choe B.-H.2, Choe Y.H.1

Created: Wednesday, 20 February 2019, 10:36 AM
P674: Predictors of response to biologics in Crohn's Diseases: A population-based study from the epi-IIRN
Year: 2022
Source: ECCO'22
Authors: Atia, O.(1); Lujan, R.(1); Greenfeld, S.(2); Kariv, R.(3); Matz, E.(4);Dotan, I.(5); Nevo, D.(6); Turner, D.(1);
Created: Friday, 11 February 2022, 3:56 PM
P674: Ustekinumab is the preferred biological agent in IBD patients with hidradenitis suppurativa failing anti-TNF therapy : results from a real-life multicenter cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Verstockt., B.(1,2)*;Vieujean, S.(3);Truyens, M.(4,5);Julsgaard, M.(6);Pugliese, D.(7);Aslan, D.(1);Prokopic, M.(8);Lim, S.(9);Viganò, C.(10);Festa, S.(11);Ramos, L.(12);Garciá, M.J.(13);Plaza, R.(14);Noviello, D.(15);Savarino, E.(16);Drobne, D.(17);Imperatore, N.(18);Ribaldone, D.G.(19);Van Dongen, J.(20);Teich, N.(21);Wahed, M.(22);Barberio, B.(23);Goren, I.(24,25);
Created: Friday, 14 July 2023, 11:12 AM
P675 CT-Scout platform, the digital solution to boost patient recruitment in inflammatory bowel disease clinical trials: A multicentre prospective observational comparative study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Bouhnik1, X. Hebuterne2, M. Raith3, A. Amiot4, C. Tanasa Stefanescu1, D. Laharie5, X. Roblin6, A. Bourreille7, S. Nancey8, N. Sabbah9, L. Peyrin Biroulet10

Created: Thursday, 30 January 2020, 10:12 AM